Potential Questions from "When the Gut Breaks the Heart"

🩺 Case-Based / Clinical History Questions

1. What are the presenting complaints in this case and how long was the symptom duration?
2. Why was this patient initially managed as IBS? What was the key history he withheld, and how did that affect his management?
3. What is the significance of the patient not reporting blood in stools during the initial gastroenterology visit?
4. What is the typical character of abdominal pain in ulcerative colitis, and how does it differ from Crohn's disease?
5. Why is an 18-year-old male an unusual demographic for both STEMI and ulcerative colitis?
6. What prompted the index cardiac event evaluation, and what was the ECG pattern seen?
7. Describe the ECG findings in anterior wall STEMI. What leads show ST elevation and what leads show reciprocal changes?
8. What is the significance of the patient having no traditional cardiac risk factors (no smoking, no alcohol, no family history of CAD)?
9. Why was DAPT started, and what was the dilemma of continuing it in the context of active colitis with GI bleeding?

🫀 Cardiology / STEMI / SCAD Questions

1. What is Spontaneous Coronary Artery Dissection (SCAD)? Define it and describe its pathophysiology.
2. What is the epidemiology of SCAD? Why is it unusual that this patient is an 18-year-old male?
3. What are the recognised predisposing conditions and precipitating stressors for SCAD?
4. What is the standard workup for a young STEMI (age < 45 years)?
5. What investigations form the autoimmune/vasculitic screen in young STEMI workup?
6. What is the role of IVUS/OCT in SCAD diagnosis?
7. What is the management of SCAD? Why is routine PCI/stenting avoided in SCAD?
8. Why are beta-blockers used in SCAD management? What benefit do they confer?
9. What is the role of antiplatelet therapy in SCAD, and how do you balance it against GI bleeding risk?
10. What is the significance of the echocardiography finding of EF 40% with RWMA in the LAD territory?
11. What does fibromuscular dysplasia (FMD) have to do with SCAD?
12. What connective tissue disorders are associated with SCAD?

🦠 Ulcerative Colitis Questions

1. Define ulcerative colitis. How does it differ from Crohn's disease in terms of distribution and histology?
2. What is the Montreal classification of UC extent? Name and define each category.
3. What are the hallmark symptoms of ulcerative colitis?
4. What are the extraintestinal manifestations of UC?
5. What is the Truelove & Witts severity criteria? What parameters does it assess and what does each grade imply for management?
6. What are the endoscopic findings of UC? What is the UCEIS (Ulcerative Colitis Endoscopic Index of Severity)?
7. What is a UCEIS score of 4/8? What does it signify in terms of disease activity?
8. What is the significance of pseudopolyps on sigmoidoscopy in UC?
9. What are the histopathological features of UC on colonic biopsy?
10. Describe the step-up management strategy for UC (mild → moderate → severe → fulminant).
11. What is the first-line treatment for mild-to-moderate UC?
12. What is the role of mesalamine (5-ASA) in UC? What dose was used in this patient and why?
13. What are the rescue therapies in Acute Severe UC that fails IV steroids? What is the Oxford criterion?
14. When is surgery indicated in UC? What is the surgical procedure of choice?
15. What is IPAA (ileal pouch-anal anastomosis)?
16. What is the role of infliximab in UC? What class of drug is it?
17. What is vedolizumab, and how does it differ mechanistically from anti-TNF agents?
18. What is tofacitinib? What is its mechanism of action?
19. How do you distinguish UC from intestinal tuberculosis (ITB) clinically, endoscopically, and histologically?
20. How do you differentiate UC from amoebic colitis?

🔬 Investigations / Lab Interpretation

1. What does microcytic hypochromic anaemia with thrombocytosis on peripheral smear suggest?
2. Why is hypoalbuminaemia seen in UC? What is its clinical significance?
3. What does a markedly raised CRP indicate in this context?
4. What is fecal calprotectin and why was it ordered? What does an elevated level indicate?
5. Why were stool cultures and stool for ova/parasites sent? What was their significance here?
6. What is occult blood testing (stool occult blood)? Why was it negative despite blood in stools?
7. What is UPCR (urine protein-creatinine ratio)? What does a value of 0.28 suggest?
8. What does reactive mesenteric lymphadenopathy on USG abdomen suggest?
9. What is the significance of minimal free fluid in the pelvis on ultrasound?
10. What are the CECT abdomen findings suggestive of UC? What key features helped distinguish it from infection?
11. What is pericolic hypervascularity on CECT and what does it indicate?

💊 Management / Hospital Course Questions

1. Why was this patient shifted to the MICU despite starting IV fluids?
2. Why did the patient develop persistent hypotension? What are the possible causes?
3. What is the role of noradrenaline as a vasopressor? Why was it chosen here?
4. Why was DVT prophylaxis given in this patient? Is there any concern about using anticoagulation in active GI bleed?
5. Why was empirical IV antibiotic therapy started before a definitive diagnosis was made?
6. How was the multidisciplinary team involved in this patient's care? What did cardiology and gastroenterology each advise?
7. How do you balance antiplatelet therapy (DAPT) with active GI bleeding in a post-SCAD patient?
8. What is the rationale for continuing DAPT after SCAD, and for how long?

🔗 The Gut-Heart Link / Discussion Questions

1. What is the proposed pathophysiological mechanism linking UC to SCAD?
2. How does systemic inflammation in UC lead to endothelial dysfunction?
3. What is the role of matrix metalloproteinases (MMPs) in SCAD pathogenesis?
4. What is vasa vasorum injury and how does it contribute to medial weakening of the coronary artery?
5. What cytokines are implicated in the inflammatory link between UC and SCAD (e.g., TNF-α, IL-6)?
6. Is UC a recognised hypercoagulable state? What mechanisms drive thrombophilia in IBD?
7. What is the current strength of evidence linking UC to SCAD? Is it causative or associative?
8. How are IBD and premature coronary artery disease related?

🧩 Differential Diagnosis Questions

1. How would you differentiate ulcerative colitis from Crohn's disease on colonoscopy?
2. What are the "skip lesions" in Crohn's disease? Does UC have them?
3. What endoscopic findings help distinguish UC from intestinal TB?
4. What is the clinical, colonoscopic, and histological triad for intestinal tuberculosis?
5. What features in this case argued against amoebic colitis?
6. What features argued against infectious colitis (bacterial)?

📋 Miscellaneous / Examiner Favorites

1. What is the Montreal classification? (Extent vs. Activity classification - know both)
2. What is the difference between UCEIS and Mayo endoscopic score?
3. What is the clinical timeline of this patient? Can you narrate it in sequence?
4. How does the presentation of SCAD differ from atherosclerotic ACS on coronary angiography?
5. What are the long-term follow-up requirements after SCAD?
6. What counselling would you give this patient at discharge regarding lifestyle and recurrence risk?
7. What is the significance of bimodal age distribution in UC?
8. What is primary sclerosing cholangitis (PSC) as an extraintestinal manifestation of UC?
9. What is pyoderma gangrenosum?
10. What is the association between UC and colorectal cancer? Does this patient need surveillance?
11. What is the role of cardiac rehabilitation in post-MI/SCAD patients?

• The SCAD diagnosis and its management (why no stent?)
• The UC workup and step-up therapy
• How the two conditions are biologically connected
• Management dilemmas (DAPT vs. GI bleed, vasopressor choice, anticoagulation)
• The Truelove & Witts criteria and UCEIS scoring

Answers: "When the Gut Breaks the Heart" - Clinical Club

SECTION 1: ULCERATIVE COLITIS

Q1. Define ulcerative colitis and describe its distribution.

• Goldman-Cecil Medicine, p. 1481

Q2. What is the Montreal classification of UC?

• S0: Clinical remission (no symptoms)
• S1: Mild - ≤4 stools/day with or without blood, no systemic disturbance
• S2: Moderate - >4 stools/day, minimal systemic disturbance
• S3: Severe - ≥6 bloody stools/day + systemic toxicity (fever, tachycardia, anaemia, raised ESR)

Q3. What are the Truelove & Witts criteria for Acute Severe UC?

• Pulse rate > 90 bpm
• Temperature > 37.8°C
• Haemoglobin < 10.5 g/dL
• ESR > 30 mm/h

• Yamada's Textbook of Gastroenterology, p. 934

Q4. What are the hallmark symptoms and extraintestinal manifestations of UC?

• Bloody diarrhoea with mucus (the cardinal feature)
• Urgency and tenesmus
• Colicky lower abdominal pain, relieved by defaecation
• In severe disease: fever, weight loss, fatigue

• Joints: Peripheral arthritis (correlates with colitis activity), ankylosing spondylitis
• Liver/Biliary: Primary sclerosing cholangitis (PSC) - does NOT correlate with colitis activity; may precede or follow IBD
• Skin: Erythema nodosum (correlates with activity), pyoderma gangrenosum
• Eyes: Uveitis / episcleritis
• Vascular: Venous and arterial thromboembolism (IBD is a recognised prothrombotic state)
• Symptom to Diagnosis, p. 482; Maingot's Abdominal Operations

Q5. How do you distinguish UC from Crohn's disease?

• Goldman-Cecil Medicine, Table 127-1

Q6. What are the endoscopic findings of UC and what is the UCEIS?

1. Loss of normal vascular pattern
2. Mucosal erythema and granularity
3. Friability (bleeds on touch) - "contact bleeding"
4. Spontaneous bleeding
5. Superficial ulceration
6. Deep ulceration

• Vascular pattern (0-2)
• Bleeding (0-3)
• Erosions/ulcers (0-3)
• Total: 0-8
  • 0-1: Remission
  • 2-4: Mild-Moderate activity
  • 5-8: Severe activity

Q7. Describe the step-up management of UC.

• Oral ± topical 5-aminosalicylates (mesalamine/5-ASA) - first-line for induction AND maintenance
• Topical mesalamine enemas are especially effective for distal disease
• This patient was started on mesalamine 2.4 g/day in divided doses - the standard mild-to-moderate dose

• Systemic corticosteroids (prednisone/prednisolone) for induction
• Steroid-sparing agents for maintenance: thiopurines (azathioprine, 6-MP)
• Biologics:
  • Anti-TNF: Infliximab (IV, chimeric mouse-human IgG1), adalimumab (SC, fully human), golimumab (SC)
  • Anti-integrin: Vedolizumab - gut-selective (blocks α4β7 integrin), fewer systemic side effects
  • Anti-IL-12/23: Ustekinumab
  • JAK inhibitors: Tofacitinib (oral, non-selective JAK inhibitor, 10mg BD for induction) and Upadacitinib (selective JAK inhibitor)

• IV corticosteroids: methylprednisolone 40-60 mg/day OR hydrocortisone 200-300 mg/day
• Reassess at day 3-5 (Oxford criteria)
• If no response → Rescue therapy: IV infliximab OR cyclosporine
• Failure of rescue → Colectomy

• Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) - "restorative proctocolectomy"
• This is curative for UC
• Indications: medically refractory disease, dysplasia/cancer, toxic megacolon, fulminant colitis
• Goldman-Cecil Medicine, pp. 1636-1660; Yamada's Textbook of Gastroenterology, pp. 944-950

Q8. What is vedolizumab and how does it differ from anti-TNF?

Q9. What is tofacitinib and what is its mechanism?

• Goldman-Cecil Medicine, p. 1638

SECTION 2: SCAD

Q10. Define SCAD and explain its pathophysiology.

1. Intimal tear first - a primary intimal disruption allows blood to enter and dissect the media
2. Vasa vasorum rupture first - spontaneous bleeding within the vessel wall (from the vasa vasorum) creates the intramural haematoma, which then compresses the true lumen from outside (no primary intimal tear)

• Fuster and Hurst's The Heart, p. 621

Q11. What is the epidemiology of SCAD and why is this patient unusual?

• SCAD accounts for 1-4% of all ACS presentations
• >90% of cases occur in women, predominantly aged 45-53 years
• SCAD is the most common cause of pregnancy-associated MI (up to 43% of peripartum MI)
• In women under 50, SCAD causes 25-35% of all MIs
• Most SCAD patients have few or no conventional cardiovascular risk factors
• High prevalence of migraine (~40%), depression (~25%), and anxiety (~15%) in SCAD patients

• Fuster and Hurst's The Heart, pp. 621-625

Q12. What are the predisposing conditions and precipitating stressors for SCAD?

• Fibromuscular dysplasia (FMD) - the most common, found in 50-86% of SCAD patients
• Connective tissue disorders: Marfan syndrome, Ehlers-Danlos syndrome, Loeys-Dietz syndrome (~5%)
• Systemic inflammatory diseases - including IBD, SLE, RA (5-12%)
• Hormonal therapy (oestrogen, progesterone, fertility treatments)

• Peripartum state (especially third trimester and postpartum)
• Intense physical exertion (isometric or extreme aerobic)
• Intense emotional stress
• Uncontrolled hypertension

Q13. Why is routine PCI/stenting avoided in SCAD?

1. Natural healing - SCAD dissections heal spontaneously in most cases (the IMH resorbs). Conservative management gives the best long-term outcomes.
2. Technical challenges - wiring the true lumen is extremely difficult; risk of propagating the dissection with the wire, balloon, or stent
3. Stent complications - long stents (often multiple) are needed to cover the entire dissection, increasing risk of restenosis, stent thrombosis, and late malapposition (as the IMH resorbs, the stent can become malapposed)
4. High failure rates - reported PCI success rates range only 47-91%, with significant complication rates

• Fuster and Hurst's The Heart, pp. 3201-3210

Q14. What is the medical management of SCAD?

• Aspirin - long-term (anti-platelet, to prevent thrombus formation at the dissection site)
• Beta-blockers - long-term; associated with lower recurrence (HR 0.36, p=0.004 in Canadian SCAD Study). Reduce shear stress on the vessel wall.
• P2Y12 inhibitor (e.g., clopidogrel) - short-term (1-12 months post-SCAD); controversial if no stenting was performed
• ACE inhibitor/ARB - if LV dysfunction is present (as in this patient - EF 40%)
• Statin - only if underlying dyslipidaemia; not routine in SCAD

• Avoid heavy isometric exercise (weight restriction <14 kg for women, <23 kg for men)
• Avoid competitive/high-intensity aerobic sports
• Minimise emotional triggers
• Cardiac rehabilitation (modified protocol)
• In women: avoid hormonal therapy and future pregnancies
• Fuster and Hurst's The Heart, pp. 3211-3213

Q15. What is the DAPT dilemma in this patient?

• Recent SCAD - LAD territory, with residual LV dysfunction (EF 40%)
• Stopping DAPT risks coronary re-thrombosis at the dissection site or stent thrombosis if stented
• Beta-blocker + aspirin are recommended long-term regardless

• Active UC with ongoing GI mucosal bleeding
• Adding P2Y12 inhibitor (clopidogrel) to aspirin increases GI bleeding risk substantially
• Anaemia already present (Hb 7.8) - bleeding further worsened

SECTION 3: ECG in STEMI

Q16. Describe the ECG findings in anterior wall STEMI and what are the reciprocal changes?

• ST elevation in leads V1-V4 (anteroseptal: V1-V3; anterior: V3-V4; anterolateral: V4-V6, I, aVL)
• The LAD supplies the anterior wall and apex; the territory of ST elevation maps to the affected zone

• Anterior STEMI may show ST depression in one or more inferior leads (II, III, or aVF)
• Reciprocal ST depression in leads opposite the infarct territory increases specificity for true AMI and is associated with larger infarction, higher rate of adverse events, and higher mortality

• Rosen's Emergency Medicine, pp. 97-100

SECTION 4: THE GUT-HEART LINK

Q17. What is the proposed mechanism linking UC to SCAD?

Active UC
    ↓
Systemic inflammation (↑CRP, ↑TNF-α, ↑IL-6)
    ↓
Endothelial dysfunction
    ↓
Matrix metalloproteinase (MMP) activation
    ↓
Vasa vasorum injury + medial weakening of coronary artery wall
    ↓
Intimal tear / Intramural haematoma
    ↓
Coronary Artery Dissection (SCAD)

• Active IBD is a well-recognised hypercoagulable, pro-inflammatory state independently linked to premature coronary artery disease and venous/arterial thromboembolism
• Systemic inflammatory and autoimmune conditions are now grouped among the recognised predisposing arteriopathies for SCAD (they account for 5-12% of all SCAD)
• MMPs (matrix metalloproteinases) are enzymes that degrade extracellular matrix components - when upregulated by inflammation (TNF-α, IL-6), they can weaken the structural integrity of the coronary arterial wall, specifically the collagen and elastin in the media
• Vasa vasorum are the tiny vessels supplying the wall of large arteries. Inflammatory injury to vasa vasorum can cause spontaneous bleeding within the vessel wall, creating the intramural haematoma

Q18. What is the IBD-thrombosis relationship?

• Elevated acute-phase reactants (fibrinogen, factor VIII, von Willebrand factor) during active flares
• Thrombocytopaenia is unusual; UC more commonly causes reactive thrombocytosis (as seen in this patient - thrombocytosis on peripheral smear is a marker of active inflammation/blood loss)
• Decreased natural anticoagulants (protein C, protein S, antithrombin III) during active disease
• Immobility (hospitalised patients) + dehydration further increases clot risk
• Both venous thromboembolism (DVT, PE) and arterial events (stroke, MI) are increased

SECTION 5: INVESTIGATIONS

Q19. What does the peripheral smear pattern of microcytic hypochromic anaemia + thrombocytosis suggest?

1. Iron-deficiency anaemia - microcytic hypochromic red cells = depleted iron stores from chronic GI blood loss
2. Reactive thrombocytosis - elevated platelet count is a reactive marrow response to:
   • Chronic blood loss (iron deficiency itself is a thrombocytosis trigger)
   • Active systemic inflammation (IL-6 stimulates thrombopoietin production)

• Goldman-Cecil Medicine, p. 1601

Q20. What is fecal calprotectin and what does it indicate?

• Elevated (>50-200 μg/g): Indicates active mucosal inflammation - differentiates IBD from IBS
• Normal: Suggests remission or functional bowel disease (IBS)
• Used to monitor disease activity and assess response to treatment
• Calprotectin levels in IBD are 10-50x higher than in IBS

Q21. What is the significance of hypoalbuminaemia in this context?

1. Protein loss into an inflamed gut lumen (exudative enteropathy)
2. Decreased hepatic synthesis due to active inflammation (albumin is a negative acute-phase reactant - levels fall when IL-6 is high)
3. Malnutrition from decreased oral intake

SECTION 6: HOSPITAL COURSE / MANAGEMENT DILEMMAS

Q22. Why was the patient hypotensive despite IV fluid resuscitation?

1. Sepsis physiology from the inflamed/infected gut (distributive shock - vasodilation from systemic inflammation)
2. Severe anaemia (Hb 7.8 g/dL) - reduced oxygen-carrying capacity contributing to haemodynamic compromise
3. Hypovolaemia from ongoing fluid losses (diarrhoea, vomiting)
4. Cardiac dysfunction - LV ejection fraction of only 40% (post-SCAD anterior MI) limits the heart's ability to compensate with increased cardiac output during a vasodilatory shock state

Q23. Why was noradrenaline used as the vasopressor?

• Strong α1-adrenergic agonist - vasoconstriction, increases SVR, raises blood pressure
• Moderate β1 activity - mild positive inotropy
• Preferred over dopamine (higher arrhythmia risk) and pure α-agonists (excessive vasoconstriction)
• Particularly suitable in this case because the cardiac dysfunction (EF 40%) benefits from the mild inotropic support alongside vasoconstriction

Q24. How would you counsel this patient at discharge?

• Adherence to mesalamine is essential - it maintains remission and reduces colorectal cancer risk
• Colonoscopic surveillance for colorectal cancer starting 8-10 years after diagnosis
• Dietary advice (low-residue during flares), avoid NSAIDs (worsen colitis)
• Watch for flare symptoms - increase in stool frequency, rectal bleeding → early review

• Continue aspirin and beta-blocker long-term
• Avoid intense isometric exercise (heavy lifting >14 kg)
• No competitive or high-intensity aerobic sports
• Avoid emotional triggers
• Cardiac rehabilitation (modified protocol)
• Treat underlying inflammation (controlling UC may reduce SCAD recurrence risk)
• Regular cardiology follow-up for EF recovery monitoring
• Echocardiogram follow-up at 3-6 months

Sources: Goldman-Cecil Medicine (26th ed.), Fuster and Hurst's The Heart (15th ed.), Yamada's Textbook of Gastroenterology (7th ed.), Rosen's Emergency Medicine, and the presentation slides.